The latest (pictured right) included an interview with Volition CEO, Cameron Reynolds, talking about Volition’s latest acquisition and also covering a series of other recent milestones and a look ahead to their activities in 2020.
The announcement gave details about the closing of the acquisition of the epigenetic reagent company Octamer GmbH (“Octamer”) by its subsidiary Belgian Volition SPRL for approximately $725,000, consisting of cash and shares of restricted common stock of Volition. This strategic acquisition helps secure the supply of one of the key components of Volition’s Nu.Q(TM) tests, the recombinant nucleosome used as the calibrant.
Volition also announced the receipt of additional non-dilutive funding in the form of a $550,000 (Euro 500,000) unsecured loan from Namur Invest to assist with the Octamer acquisition. This takes the total non-dilutive funding provided by the Namur Regional Government and associated agencies to over $7 million to-date.
Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer. Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases.